Childhood Idiopathic Nephrotic Syndrome
Conditions
Keywords
rituximab, idiopathic nephrotic syndrome, minimal change disease, focal and segmental glomerulosclerosis
Brief summary
Background Idiopathic nephrotic syndrome is a rare disease beginning during childhood and treated with immunosuppressants (i.e. steroids, mycophenolate mofetil, cyclophosphamide, cyclosporine). Renal function of patients suffering from severe, steroid-dependent nephrotic syndrome with failure or toxic side effects of other immunosuppressant treatments is a major matter of concern. Cyclosporine endangers renal parenchyma (fibrosis) in these patients who must take this treatment for years. At the same time, low doses of cyclosporine allow proteinuria to reappear, which provokes degradation of renal function by focal segmental glomerulosclerosis. Some recent data lead to the conclusion that Rituximab may be effective in such a disease, with a cyclosporin sparing effect. Purpose The aim of the study is to evaluate the efficacy of Rituximab versus placebo in the treatment of pediatric patients suffering from severe cyclosporine-dependent nephrotic syndrome. Abstract Patients will be included in the study in a period of remission of proteinuria. Two infusions of Rituximab - at the dose of 375 mg/m²- or placebo will be administered at one week of interval. Other immunosuppressant treatments will be gradually tapered off with the same tapering pattern in both groups. In case of relapse of nephrotic syndrome, the blinding code will be broken. Rituximab will then be infused to patients having received placebo.
Detailed description
After infusions of Rituximab or placebo, patients will be examined by their nephrologist on a monthly basis during five months. Follow up will be focused on proteinuria, albuminemia, lymphocyte phenotyping and Rituximab pharmacokinetics
Interventions
DRUGRituximab
two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
DRUGPlacebo
two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
Sponsors
Hoffmann-La Roche
University Hospital, Limoges
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Male or Female patients over 2 and under 18 years, with an idiopathic nephrotic syndrome (NS) * Steroid Sensitive Nephrotic Syndrome (according to the French pediatric protocol). NEPHRUTIX * Calcineurin inhibitor Dependent NS or NS for which anticalcineurin treatment has not been effective. Others immunosuppressive treatments (MMF) must have failed to control the disease activity. * Effective contraception for girls of childbearing age. * The patient is able to understand and has signed a written informed consent OR the parent or legal guardian is able to understand and has signed a written informed consent, which must be obtained prior to the initiation of any study procedure
Exclusion criteria
* Terminal renal failure requiring dialysis/transplantation * Transcutaneous oxygen stauration \< 97% * Clinical or Radiological brochopulmonar or pleural abnormality * Asymptomatic carrier of Hepatitis B virus our history of Hepatitis B * Contraindication to Rituximab (RTX) * Parents/patient refusing to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proteinuria with relapse of nephrotic syndrome (Serum albumin < 30 g/L) within 5 months | 5 months | Proteinuria with relapse of nephrotic syndrome (Serum albumin \< 30 g/L) within 5 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| - dosing of rituximab for toxicity during and/or after infusion | 5 months | \- toxicity during and/or after infusion |
| - dosing of rituximab for pharmacokinetics | 5 months | \- dosing of rituximab for pharmacokinetics |
| - dosing of lymphocyte | 5 months | \- lymphocyte phenotyping |
| Pediatric Quality of life inventory | 5 months | Pediatric Quality of life inventory |
Countries
Belgium, France
Outcome results
None listed